Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Ultragenyx Pharmaceutical Inc. RARE
$47.21
+$0.1 (0.20%)
На 18:00, 12 мая 2023
+139.74%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
3340673849.00000000
-
week52high
68.68
-
week52low
33.36
-
Revenue
363329000
-
P/E TTM
-5
-
Beta
0.93598600
-
EPS
-9.96000000
-
Last Dividend
0.00000000
-
Next Earnings Date
04 мая 2023 г. в 20:00
Описание компании
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Evercore ISI Group | In-Line | Outperform | 01 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 29 июл 2022 г. |
| Stifel | Buy | Buy | 01 июл 2022 г. |
| Goldman Sachs | Neutral | Neutral | 24 мая 2022 г. |
| Piper Sandler | Overweight | Overweight | 19 мая 2022 г. |
| Guggenheim | Buy | Neutral | 13 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 03 ноя 2022 г. |
| Morgan Stanley | Overweight | Overweight | 03 ноя 2022 г. |
| Credit Suisse | Outperform | Outperform | 03 ноя 2022 г. |
| Baird | Outperform | Neutral | 03 ноя 2022 г. |
| Goldman Sachs | Neutral | Neutral | 04 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| KAKKIS EMIL D | D | 541108 | 19582 | 30 дек 2022 г. |
| Huizenga Theodore Alan | D | 16197 | 2031 | 21 дек 2022 г. |
| Dier Mardi | D | 66695 | 1629 | 14 окт 2022 г. |
| Dier Mardi | D | 68324 | 3484 | 12 окт 2022 г. |
| Dier Mardi | A | 71808 | 20000 | 16 сент 2022 г. |
| Huizenga Theodore Alan | A | 18094 | 1000 | 01 сент 2022 г. |
| Sanders Corazon (Corsee) D. | A | 6245 | 6245 | 24 июн 2022 г. |
| Sanders Corazon (Corsee) D. | A | 7195 | 3300 | 24 июн 2022 г. |
| WELCH DANIEL G | A | 6245 | 6245 | 24 июн 2022 г. |
| WELCH DANIEL G | A | 17745 | 3300 | 24 июн 2022 г. |
Новостная лента
Ultragenyx to Present at Bank of America's 2023 Health Care Conference
GlobeNewsWire
05 мая 2023 г. в 16:01
NOVATO, Calif., May 05, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company's chief executive officer and president, will present at Bank of America's 2023 Health Care Conference on Wednesday, May 10, 2023, at 9:20 a.m. PT.
Ultragenyx (RARE) Q1 Earnings and Revenues Miss Estimates
Zacks Investment Research
05 мая 2023 г. в 09:54
Ultragenyx Pharmaceutical's (RARE) first-quarter 2023 earnings and revenues miss estimates. The company maintains its 2023 guidance.
Ultragenyx Pharmaceutical Inc. (RARE) Q1 2023 Earnings Call Transcript
Seeking Alpha
04 мая 2023 г. в 23:25
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q1 2023 Earnings Conference Call May 4, 2023 5:00 PM ET Company Participants Joshua Higa - Vice President and Head of Investor Relations Emil Kakkis - Founder, President and Chief Executive Officer Erik Harris - Chief Commercial Officer and Executive Vice President Eric Crombez - Chief Medical Officer and Executive Vice President Aaron Olsen - Senior Vice President of Corporate Strategy and Finance Ted Huizenga - Chief Accounting Officer Conference Call Participants Gena Wang - Barclays Maury Raycroft - Jefferies Dae Gon Ha - Stifel Joon Lee - Truist Securities Yaron Werber - TD Cowen Kristen Kluska - Cantor Fitzgerald Michael Riad - Morgan Stanley Joel Beatty - Baird Operator Good afternoon, and welcome to the Ultragenyx First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Ultragenyx (RARE) Reports Q1 Loss, Lags Revenue Estimates
Zacks Investment Research
04 мая 2023 г. в 19:01
Ultragenyx (RARE) came out with a quarterly loss of $2.33 per share versus the Zacks Consensus Estimate of a loss of $1.97. This compares to loss of $2.19 per share a year ago.
Ultragenyx to Host Conference Call for First Quarter 2023 Financial Results and Corporate Update
GlobeNewsWire
27 апр 2023 г. в 16:05
NOVATO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Thursday, May 4, 2023, to discuss its financial results and corporate update for the quarter ending March 31, 2023.